Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Stocks at 52-Week Lows Poised for a Powerful Rebound
With strong market performance in recent periods, finding stocks priced at a discount can be challenging. However, examining stocks at 52-week lows may identify equities valued below their potential.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
My April Dividend Stock Buys With Yields Up To 12%
My April Dividend Stock Buys With Yields Up To 12%
Gilead Sciences Finally Starts Succeeding
Gilead Sciences has a strong track record in curing Hepatitis C and a successful HIV business. The company has struggled with acquisitions but is expected to generate strong shareholder returns. Gi...
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences (GILD) Rises But Trails Market: What Investors Should Know
Gilead Sciences (GILD) reachead $73.41 at the closing of the latest trading day, reflecting a +0.2% change compared to its last close.
Gilead CAR-T cancer therapy capacity to quadruple by 2026
Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech's manufacturing processes, an executive in charge of that ...
Gilead Sciences, Inc. (GILD) Leerink Partners Global Biopharma Conference (Transcript)
Gilead Sciences, Inc. (GILD) Leerink Partners Global Biopharma Conference (Transcript)
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
In the most recent trading session, Gilead Sciences (GILD) closed at $73.66, indicating a +1.42% shift from the previous trading day.
Gilead (GILD) & MRK's HIV Oral Combo Shows Efficacy in Phase II
Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals wit...
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 44th Annual Health Care Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) TD Cowen 44th Annual Health Care Conference March 5, 2024 12:50 PM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Participants...
Related Companies